Basic Information

Gene symbol VEGFA Synonyms L-VEGF, MVCD1, VEGF, VPF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description vascular endothelial growth factor A

GTO ID GTC0029
Trial ID NCT00327470
Disease Age-Related Macular Degeneration
Altered gene VEGFA
Therapeutic/Target gene Target gene
TherapyAptamer
Treatment Macugen|pegaptanib|EYE001
PhasePhase4
Recruitment statusTerminated
TitleA 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV)
Year2006
CountryAustria|Belgium|Canada|Czech Republic|Denmark|Finland|France|Germany|Greece|Italy|Poland|Portugal|Spain|Turkey|United Kingdom
Company sponsorPfizer
Other ID(s)A5751017

Clinical Result

Cohort1: every 6 weeks
Administration route intravitreal injection
Dosage Pegaptanib Sodium, 0.3 mg, every 6 weeks for 48 weeks
Pts 107
Age Adult, Older_Adult
Outcome Mean Change From Baseline Through Week 54 in Distance Visual Acuity (VA) in Subjects With Early and Established CNV Lesions:Mean (Standard Deviation):-4.30(14.57)
Adverse reactions 23/107(Blood and lymphatic system disorders; Cardiac disorders; Ear and labyrinth disorders; Eye disorders; Gastrointestinal disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Respiratory, thoracic and mediastinal disorders; Surgical and medical procedures; Vascular disorders)
References PMID: 22872673
Cohort2: every 12 weeks
Administration route intravitreal injection
Dosage Pegaptanib Sodium, 0.3 mg, every 12 weeks (ie, Weeks 60, 72, 84, and 96)
Pts 179
Age Adult, Older_Adult
Outcome Mean Change From Baseline Through Week 54 in Distance Visual Acuity (VA) in Subjects With Early and Established CNV Lesions:Mean (Standard Deviation):-5.51(15.08)
Adverse reactions 32/179(Cardiac disorders; Eye disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Infections and infestations; Infections and infestations; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Reproductive system and breast disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Surgical and medical procedures; Vascular disorders)
References PMID: 22872673

Relationship Graph

Overview of Knowledge Graph